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Romano Demicheli1* and Federico Ambrogi2Abstract
Background: Breast cancer mortality steadily declined from the 1990s and this has been attributed to early
detection and/or to improvements in therapy. Which of those two has had the greater impact is a subject of
contention.
Methods: A database of 386 patients, enrolled in a randomized clinical trial on the effect of adjuvant
chemotherapy (CMF), was analysed. The probabilities of recurrence and death were estimated by the Fine and
Gray’s model and by the Cox model. Time dependent covariate and interaction effects were investigated by
additive models. Absolute risk reductions (ARR) related to adjuvant treatment or to tumour size [diameter≤ 2 cm (T1)
or >2 cm (T2/T3)] were estimated.
Results: CMF-related reduction in recurrence emerges early, reaches a maximum level at 3 years and persists at a
constant level thereafter. Tumour-size-related recurrence reduction, after a maximum at 3 years, displays a progressive
regular reduction approaching zero. Patients with any tumour size, when given CMF, exhibit mortality reduction that
displays an early regular increase and continues to a persistent plateau. In contrast, tumour-size-related mortality reduction
reaches a maximum at 5–7 years and then regularly drops to very low values for patients of both trial arms.
Conclusions: Findings reveal that there is a different time-dependent benefit from chemotherapy and from smaller
tumour size at diagnosis. The benefit from adjuvant chemotherapy is long-lasting for patients with any tumour size
while the early benefit of diagnosing smaller tumours substantially decreases afterwards. Treatment improvements have
probably had greater impact on the mortality reduction than mammography screening.Background
The use of adjuvant chemotherapy and hormonal therapy
for early breast cancer has strongly increased over the
last three decades, mainly following the worldwide
overview analyses of randomised clinical trials assessing
the effects of adjuvant therapy, showing significant
benefits in disease-free and overall survival [1,2]. Survival
improvements associated with the use of adjuvant therapies
were estimated to be reductions in the annual odds
of death ranging from 8% to 28%, depending on the
type and duration of therapy, the age of the patients,
and the characteristics of the tumour [1,2].* Correspondence: demicheliromano@istitutotumori.mi.it
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article, unless otherwise stated.Breast cancer mortality was relatively stable until the
late 1980s and subsequently slowly and steadily declined
in Canada, USA and several countries of Europe [3].
This reduction in mortality cannot be attributed to
declines in breast cancer incidence since that has
been increasing during the past 30 years in North
America and Europe [3,4]. Thus, reductions in breast
cancer mortality, which has been improving from the early
1990s, have been attributed largely to the prolongation of
life among women with the disease [4,5]. Although
reasons for the reduction in mortality have been the
object of much debate, improvements in early detection
and/or improvements of treatments are currently accepted
as leading explanations [6,7].
Analyses of factors responsible for the observed breast
cancer mortality decline are difficult to conduct on a
population basis because tumour registries often haveed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tumour and treatments [5]. Without such information, it
is impossible to disentangle the effects of early detection
from that of treatments, while simultaneously taking
into account secular trends in characteristics of women
or their disease. The question has also been addressed
by mathematical models [7,8] for which, however, slight
variations in modelling assumptions can result in marked
changes in estimated effects, even when common sources
of data are adopted [7]. A qualitative agreement between
models confirms that both screening and therapy contrib-
uted to the decline in mortality although the separate
quantitative contributions remain elusive.
There has been extensive analysis of screening
mammography effectiveness (e.g. methodological difficulties
in trial project and analysis, selective detection of certain
types of tumours and breast cancer over-diagnosis) [9].
Nevertheless, screening results in an established effect, i.e.
the increased frequency of smaller tumour size at the time
of diagnosis that has been observed in every trial that
has been conducted. Furthermore, given that a substantial
number of breast cancer patients are given adjuvant
treatments, there is a crucial question involving the
relative improvements in patient prognosis resulting from
the reduction in tumour size and the administration of
systemic treatment when jointly accomplished. In this
report, we indirectly approached this question in the quite
specific “experimental” setting of patients with early breast
cancer with axillary node involvement, by assessing
adjuvant treatment effectiveness according to tumour size
at diagnosis in a randomized clinical trial comparing adju-
vant chemotherapy to no post-surgical systemic treatment.
We considered that, although limited to chemotherapy only
and to a particular clinical setting that is much simpler than
the population level, the study could provide some useful
information about this complex issue.
Methods
The classical randomized clinical trial carried out at
the Istituto Nazionale Tumori in Milan, Italy, to as-
certain the effectiveness of adjuvant Cyclophosphamide,
Methotrexate and Fluorouracil (CMF) in comparison to
no post-mastectomy systemic therapy [10,11] was analysed.
The protocol design was approved by both the Scientific
Committee and the Ethic Committee of the Istituto
Nazionale Tumori and informed consent was obtained
from all patients. It should be emphasized that no mammo-
graphic screening was underway at that time.
Patients were stratified according to age, the number
of axillary nodes involved, and the type of radical
mastectomy (conventional or extended) and were then
randomly assigned to receive either CMF for 12 cycles or
no further treatment. Neither postoperative irradiation
nor adjuvant endocrine therapy was administered.A total of 386 patients were enrolled: 179 surgery alone
and 207 surgery plus adjuvant chemotherapy. CMF
treatment consisted of the cyclic administration of
Cyclophosphamide (100 mg per square meter of body-
surface area orally from day 1 to 14), Methotrexate (40 mg
per square meter intravenously on days 1 and 8), and
Fluorouracil (600 mg per square meter intravenously on
days 1 and 8). Each cycle was followed by a two-week rest
period (day 15 to 28). Chemotherapy was started two to
four weeks after mastectomy.
Before surgery, all patients underwent a complete
physical examination, x-ray study of the chest and skeleton
(skull, spine, pelvis, and upper third of femurs), bilateral
mammography, differential blood count with platelet count,
and biochemical tests. In the absence of symptoms, physical
examination was performed every 3 weeks during the first
year, every 6 months for the next 4 years, and every
12 months for the following 10 years. Biochemical tests,
chest X-ray, and bone X-ray or bone scanning were
performed every six to eight months during the first
five years and yearly thereafter. Mammography was
planned once a year. After the 15th year of follow-up,
the patients were examined every 12 to 18 months.
In patients with suspicious or controversial radiologic
findings, examinations were performed more often.
Liver ultrasound scan was performed only if there were sus-
picious clinical or biochemical findings. Detailed descrip-
tion of patient characteristics is reported elsewhere [10,11].
Event timing was calculated from the date of surgery.
Recurrence was considered to have occurred with the
first documented evidence of new manifestations of
disease in loco-regional areas (including homolateral
supraclavicular adenopathy), distant sites or any combin-
ation of these sites. Contralateral breast tumours, second
primary cancers and deaths during complete clinical
remission were not considered recurrence. Recurrences
were analysed considering deaths during complete clinical
remission as competing risk. Death from all causes was
used as the end-point for overall survival.
Cox model was used to estimate the probability of
death according to tumour size at diagnosis and adju-
vant treatment. The presence of time by covariates
interaction (time-dependent covariate effects either
linear, log or spline transform) and between covariates
interaction (also time-dependent) were tested using
likelihood ratio or Wald test. Absolute risk reduction
(ARR) due to adjuvant treatment was estimated for
the different tumour sizes. ARR for small tumour size
compared to large tumour size was also estimated for
patients receiving and not receiving adjuvant treat-
ment. Non-parametric bootstrap was used for confi-
dence interval of estimated survival curves. The same
calculations were performed for recurrences using the
Fine and Gray’s model.
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dependent covariate and interaction effects, both for overall
survival, using the Aalen model [12], and recurrences
considering competing risks, using the Scheike model [13].
The additive modelling approach allows investigating each
covariate effect non-parametrically, i.e. considering each
effect non-constant through time. Covariate effects are not
multiplicative on the hazard scale, as for Cox model, but
additive, and usually results are displayed considering the
cumulative hazard function.
Results
Main patient characteristics are reported in Table 1. In
particular, the frequency of tumours with diameter of
2 cm or less (T1) and larger tumours (T2/T3) are well
balanced in the two arms. The median (and minimum)
follow-up time was 15.8 years.
According to Fine & Gray’s model for the analysis
of recurrences, evidence for a time-dependent effect
(natural cubic spline function of time) for both tumour
size and adjuvant therapy was found (p-value for time by
tumour size interaction: 0.007; p-value for time by
adjuvant therapy interaction: 0.037). However, no
evidence for interaction (even time-dependent) between
tumour size and CMF treatment was found (p = 0.64).
Similar results were found according to the Scheike
additive model (tumour size, p = 0.001; adjuvant therapy,
p = 0.007; interaction, p = 0.33).
Figure 1 displays the probability of recurrence through
follow-up time, sorted by tumour size, of patients from
the two trial arms, estimated through the Fine and
Gray’s model. Table 2 reports the same probabilities
with their 95% confidence intervals at three different
follow-up times. To better distinguish the dynamics of the
clinical impact due to tumour size and adjuvant treatment,
ARRs through the analysed 15 years of follow-up are
reported in Figure 2. The analysis of all these quantitative
data supports the following statements:Table 1 Main patient characteristics
Characteristic Controls CMF
Number of patients 179 207
Tumour size
T1 95 103
T2/T3 84 104
Axillary positive nodes
1–3 126 140
> 3 53 67
Menopausal status
Pre-menopause 87 104
Post-menopause 92 103
T1: tumour size ≤ 2 cm; T2/T3: tumour size > 2 cm.➢ Administration of adjuvant CMF reduces the
cumulative recurrence rate in both patients with T1
and T2/T3 tumours. The reduction is time-dependent
on the relative hazard scale, and ARR shows an early
increase to a maximum value at the third year and then
decreases to a plateau, which is reached at about the
fifth year and persists afterwards up to the end of
the observed follow-up. The long-lasting recurrence
reduction due to CMF is about 14-16% for patients
with T2/T3 tumours and 8-10% for patients with T1
tumours. As already indicated, CMF-related reductions
in the two patient subsets are not significantly different.
➢ T1 instead of T2/T3 tumour size at diagnosis has
impact on the recurrence rate in both patients treated
with CMF and controls. In both cases the recurrence
reduction on the relative hazard rate scale is
time-dependent. ARR maximum value is reached
nearly at the third year and displays a progressive
and fairly regular reduction afterwards, at least until
the end of the analysed time span, when it is
apparently approaching zero.
According to the Cox model for the analysis of mortality
hazard, evidence for a time-dependent effect (linear) for
tumour dimension was found (p-value for time by tumour
size interaction: 0.007; p-value for time by adjuvant
therapy interaction: 0.62). No evidence for interaction
(even time-dependent) between tumour size and CMF
treatment was ascertained (p = 0.68). Similar results
were obtained according to Aalen additive model as
well (tumour size, p = 0.04; adjuvant therapy, p = 0.48;
interaction, p = 0.67).
Table 3 displays the fraction, sorted by tumour size, of
patients from the two trial arms who died within different
follow-up times, estimated through the Cox model.
To indicate the dynamics of the impact on mortality
due to tumour size and adjuvant treatment, ARRs through
the analysed 15 years of follow-up are reported in Figure 3.
The analysis of all these quantitative data supports
the following statements.
➢ Administration of adjuvant CMF reduces the
cumulative mortality in patients with both T1 and
T2/T3 tumours. The reduction displays an early
regular increase to a plateau persisting up to the end
of the observed follow-up. The long-lasting mortality
reduction due to CMF is about 7-8%, independent on
the tumour size.
➢ T1 instead of T2/T3 tumour size at diagnosis has a
nearly similar effect on the mortality of patients of both
trial arms. The mortality reduction reaches its
maximum (12-13%) at 5–7 years. Although this
maximum reduction is notably larger than the
corresponding above reported reduction due to CMF
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Figure 1 Probabilities of recurrence estimated using the Fine and Gray’s model with time dependent covariate effects for patients
with different tumour size and randomized in the two trial arms.
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low values at the end of the analysed follow-up span.
Discussion
As previously reported [10,11,14], adjuvant CMF, when
administered to node positive patients, effectively increases
the rate of living patients and patients free from disease at
all follow-up times up to 30 years. Here we add the detail
that this positive effect on the prognosis displays
time-dependence. The recurrence reduction emerges
early during the follow-up, reaches its maximum level
at about 3 years, declines slightly during the following
3–4 years and persists at a constant level thereafter
(Figure 2). This pattern is in agreement with the previous
finding that the effect of adjuvant chemotherapy on recur-
rence dynamics is confined to the first four years following
primary tumour removal [15] and to the concept that the
benefit it provides to a number of patients is long-lasting
(putative cures). The mortality reduction has an early
regular increase to a plateau persisting up to the endTable 2 Probability of recurrence of patients from the two
trial arms, sorted by tumour size, at different follow-up
times (95% confidence intervals in parenthesis)
Years of follow-up
5 10 15
Controls, T1 0.46 (0.38-0.54) 0.61 (0.52-0.69) 0.67 (0.59-0.75)
Controls, T2/T3 0.62 (0.53-0.70) 0.72 (0.64-0.80) 0.76 (0.67-0.83)
CMF, T1 0.38 (0.30-0.46) 0.51 (0.42-0.59) 0.59 (0.50-0.67)
CMF, T2/T3 0.46 (0.38-0.55) 0.57 (0.49-0.65) 0.62 (0.54-0.70)of the observed follow-up, once again in agreement with
the concept of putative CMF related cures. Although
reductions in recurrence and mortality are larger for
patients diagnosed with tumour diameter more than 2 cm
than for patients with smaller tumours, the differences
observed in the present database are not statistically
significant.
Smaller tumour size at diagnosis elicits better recurrence-
free survival for both untreated patients and patients
receiving adjuvant CMF (Figure 2). This positive effect is
time-dependent and displays an early rapid increase until
the third year, when the gain is utmost, but then drops
regularly afterwards, without apparently any trend towards
a further plateau. The corresponding mortality associated
to smaller tumours at diagnosis is somewhat similar for
both arms of the randomized trial and displays a trend to
vanishing with increasing follow-up time, compared to
persistence of CMF related improvement (Figure 3).
That a) the same behaviour is detectable in both subsets of
treated and control patients and b) similar time-dependent
behaviour was previously reported for another breast
cancer series [16] contributes evidence to the view of
a vanishing effect. Although findings may be related
to the fact that tumour size influences only the early
recurrence risk (one to four years) [17], other explanations
may not be excluded.
The results of this study show a different time-dependent
impact on the prognosis from chemotherapy and from
tumour size. Although both factors display similar early
time dependence, the benefit from adjuvant chemotherapy
appears long-lasting for patients with any tumour size,
Recurrence
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Figure 2 Adjuvant-CMF-related and tumour-size-related absolute recurrence risk reduction (ARR) for 386 early breast cancer patients
undergoing mastectomy only or mastectomy plus adjuvant CMF. Adjuvant-CMF-related ARR = Recurrence risk for controls - Recurrence risk
for CMF treated patients. Tumour-size-related ARR = Recurrence risk for T1 – recurrence risk for T2/T3.
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to drop to lower values afterwards for patients of
both trial arms.
The results of our study may be used for cautious
reasoning about mammography screening. The evaluation
of the role of mammography screening in the breast
cancer clinical approach is quite complex and involves not
only biological, clinical and statistical issues but even
financial, political and professional conflicts of interest
that poison the debate. Despite eight randomised trials
including more than 600,000 women, there are still
diverging and acrimonious views about the quantification
of the benefits of screening and screening recommenda-
tions [9]. “Screening saves lives” is strongly claimed in one
side [18], while “Which country will be first to stop
mammography screening?” is the question from the
opposite side [19]. Although the mortality reduction
is currently believed (even from screening supporters)Table 3 Probability of death of patients from the two
trial arms, sorted by tumour size, at different follow-up
times (95% confidence intervals in parenthesis)
Years of follow-up
5 10 15
Controls, T1 0.26 (0.20-0.33) 0.47 (0.39-0.55) 0.64 (0.56-0.72)
Controls, T2/T3 0.38 (0.31-0.46) 0.58 (0.49-0.66) 0.68 (0.60-0.76)
CMF, T1 0.22 (0.16-0.28) 0.41 (0.33-0.48) 0.56 (0.48-0.64)
CMF, T2/T3 0.33 (0.26-0.40) 0.51 (0.44-0.59) 0.61 (0.53-0.68)to be about half of the initially claimed 30-35%
[20-22], the contribution of mammography screening to
the general mortality decline has often been considered
substantial [23,7]. The present investigation may provide a
few elements that could be useful in the ongoing debate,
although indirectly, inferring the effect of diagnosing
smaller tumours from the effect of tumour size.
The observed time-dependence of chemotherapy and
of tumour size effects may introduce a novel question
when comparing benefits from chemotherapy and from
diagnosing smaller tumours. Indeed, the long-lasting
effect of chemotherapy and the progressively dropping
and possibly vanishing benefit of detecting smaller
tumours at diagnosis that we observed in this clinical
trial should be taken into account when comparing the
effects of the two factors at population levels.
In this study, we evaluated quantitative improvements
under the assumption that all tumours have sizes of
2 cm or less instead of more than 2 cm. If one would like
to translate our evaluations to tumour size reductions due
to mammography screening, this assumption might be
too restrictive. Indeed, only a fraction of tumours detected
by screening procedures may be down-graded from
T2/T3 category to T1 category. From the frequency
distribution of sizes of breast cancers detected in
Sweden and Canada [24] and in Edinburg [25] in
women invited for mammography and in controls, it
can be estimated that the percentage of tumour size
down-staging ranges from 10% to 24%. Therefore, the
Survival
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Figure 3 Adjuvant-CMF-related and tumour-size-related absolute mortality risk reduction (ARR) for 386 early breast cancer patients
undergoing mastectomy only (179 patients) or mastectomy plus adjuvant CMF (207 patients). Adjuvant-CMF-related ARR = Mortality risk
for controls - Mortality risk for CMF treated patients. Tumour-size-related ARR =Mortality risk for T1 – Mortality risk for T2/T3.
Demicheli and Ambrogi BMC Cancer 2014, 14:702 Page 6 of 8
http://www.biomedcentral.com/1471-2407/14/702above mentioned expected benefits should be considered
accordingly.
The study was carried out in a quite particular setting.
Indeed, although randomized clinical trials have demon-
strated survival benefits associated with the use of adjuvant
treatments, depending on the type and duration of therapy,
the age of the patients, and the characteristics of the tumour
[1], the extent to which these benefits translate to the popu-
lation outside the controlled conditions of clinical trials is
substantially unknown. Also, it should be emphasized that
present findings from node positive patients could not be
“per se” translated to women with node negative disease.
Moreover, the analysed database regarded women given
adjuvant CMF only, without any other adjuvant treatment.
Therefore, the study could not ascertain the effect of
tumour size on the prognosis of patients either receiving
more recent combination treatments (e.g. doxorubicin and/
or taxane based and HER2 targeting treatments) or adjuvant
hormone treatments or a combination of both. It may be
reasonably alleged, therefore, that our results may somewhat
underestimate the effect of adjuvant systemic treatments.
The analysed data were collected in an era prior to
mammographic screening and CMF chemotherapy is no
longer widely used in the adjuvant setting. Furthermore,
breast cancers were not classified according to modern
biologic subgroups (e.g. triple negative, hormone receptor
or Her2 positive). Yet, such facts do not lessen the
core of the results. Indeed, a) improvements in adjuvantchemotherapy by new drugs did not change the recurrence
dynamics (still unpublished data); b) analysis of recurrence
dynamics according to modern biologic subgroups
revealed similar pattern, although with different subgroup-
related levels of recurrence risk [26,27].
The results of our analysis should be evaluated keeping
in mind a few cautionary considerations. The assumption
that mammographic screening reduces the rate of T2/T3
breast cancers, in spite of its current consent, is still
lacking actual support. Most of reported data on
screening-related late stage reductions are stated as
percentages of diagnosed tumours, which are affected
by the overdiagnosis phenomenon. Additionally, there
are unexpected differences between the results from
randomized trials (late-stage reduction) and results
from population-based studies (no late-stage reduction)
[28,29], indicative that the question needs further research.
A second point at present poorly clarified regards the
biology of breast cancer. Indeed, the course of clinically
diagnosed tumours might be somehow dissimilar from the
course of tumours with the same size detected by screening
[30]. This occurrence would introduce, therefore, an
additional prognostic factor.
Conclusion
In conclusion, the results of our hypothesis generating
study, which evaluates tumour-size-related prognosis
changes in a particular setting, suggest that the effect of
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to the early post-surgery time in comparison with the
corresponding effect of adjuvant therapies, which seems
to play a more prominent and long-lasting role. This
view is consonant recent reports [31,23] showing that in
Denmark and Norway (two “model countries” in respect
to mammography screening) mortality reductions have
been detected in both screened and non-screened
areas since early 90’s (when adjuvant therapy was rou-
tinely introduced) and that the estimated mortality
declines by area were similar [31] or only moderately
different with a minor fraction attributable to screen-
ing [23]. In the absence of other opposing indications,
we suggest that the mortality reduction for breast
cancer patients observed during the last decades might be
mainly attributed to treatment improvements, even if
mammography screening may have been contributory to
some extent.
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